If a gene therapy is deemed commercially unviable, its development may be paused or abandoned. At the end of 2024, Pfizer terminated its partnership with Sangamo Therapeutics on a haemophilia A gene ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to fend off criticism from an activist investor that has argued the ...

WALTHAM, MASSACHUSETTS / ACCESS Newswire / February 4, 2025 / Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at leveraging advanced analytics and knowledge graph AI ...

Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance (5) provided on December 17, 2024.

Ahead of next Tuesday's earnings release, Pfizer seems undervalued based on current price of $26.55 & valuation of $150bn. But is it madness to expect upside? Quite possibly it is. My DCF analysis ...

The Papua New Guinea government is reportedly ready to pass a legislation to regulate its media, which journalism advocates have said could have serious implications for democracy and freedom of ...

Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people familiar with the matter. Starboard did not nominate any directors ...

Activist Starboard Value has decided not to pursue a proxy battle with Pfizer. Starboard built a $1 billion stake in Pfizer in October and reportedly planned to push for changes. Get two weeks of ...

Recently, Pfizer found itself in the agency's crosshairs thanks to one of its M&A plays. Now, Pfizer—which purchased neuroscience specialist Biohaven for $11.6 billion in 2022—is committing ...

Pfizer acquired Biohaven for $11.6bn in October 2022 based on a strong sales forecast for Nurtec ODT. Image credit: Shutterstock/Molly Woodward. Pfizer has agreed to pay $59.7m to resolve illegal ...